Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Among authors: gunduz s. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Use of chemotherapy at the end of life in Turkey.
Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatlı AM, Bozcuk H, Ozdogan M, Coskun HS. Sezgin Goksu S, et al. Among authors: gunduz s. BMC Palliat Care. 2014 Nov 19;13(1):51. doi: 10.1186/1472-684X-13-51. eCollection 2014. BMC Palliat Care. 2014. PMID: 25435808 Free PMC article.
Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, Kargi A, Kargi B, Koral L, Ibrahim Bassorgun C, Unal D, Mutlu H, Senol Coskun H, Ozdogan M, Bozcuk H. Arslan D, et al. Among authors: gunduz s. J BUON. 2015 Mar-Apr;20(2):573-9. J BUON. 2015. PMID: 26011352 Free article.
Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ. Mutlu H, et al. Among authors: gunduz s. J Cancer Res Ther. 2017 Jul-Sep;13(3):510-513. doi: 10.4103/0973-1482.161933. J Cancer Res Ther. 2017. PMID: 28862218 Free article.
280 results